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Letters
Acute Epiglottitis due to Pasteurella
multocida in an Adult without Animal
Exposure
To the Editor:  Pasteurella multocida infection in
humans usually involves animal contact, most
commonly with a domestic dog or cat (1). Epiglot-
titis due to human P. multocida infection asso-
ciated with animal contact is very rare (2-4). We
report a case of epiglottitis due to P. multocida
not associated with animal contact.
A 44-year-old patient was admitted to the
hospital with fever, throat fullness, and drooling.
He had been healthy until 12 hours before admis-
sion when he noticed difficulty in swallowing
liquids; anterior neck discomfort and fever fol-
lowed, and soon he could not swallow his saliva.
When he arrived at the Emergency Depart-
ment of Montefiore Medical Center on September
23, 1996, the patient was mildly toxic and had an
oral temperature of 103.2°F. Pulse was 110 and
blood pressure 110/70. He was drooling. He had
mild anterior neck tenderness, no cervical adeno-
pathy, no pharyngitis on inspection of the oro-
pharynx, and no palate deviation. The heart, lungs,
abdomen, and skin showed no abnormalities. A
lateral neck radiograph showed an enlarged
epiglottis (“thumb sign”). Indirect laryngoscopy
confirmed inflamed and edematous epiglottis
and supraglottic structures. A culture of the
epiglottis was not performed.
On admission, the patient had a hemoglobin
of 1.9 g/dL; hematocrit was 48%; white blood
cell count was 14,100/mm3; and platelet count
was 170,000/mm3. A machine differential count
showed 86% granulocytes, 9% lymphocytes,
and 5% monocytes.
The patient was treated with dexamethasone
and ceftriaxone. The fever abated rapidly, and all
symptoms resolved. Repeat laryngoscopy on day
3 confirmed resolving epiglottitis. Blood cultures
taken on admission grew gram-negative, oxidase-
positive bacilli that did not grow on MacConkey
agar (BBL, Cockeysville, MD) in two sets, both
aerobically and anaerobically. The isolate was
identified as P. multocida by the Vitek GNI card
(BioMérieux-Vitek, Inc., Hazelwood, MO). Kirby-
Bauer susceptibility testing demonstrated suscep-
tibility to penicillin. Because of the patient’s
marked improvement after treatment with
Furthermore, this influence occurs in an allele-
specific fashion (2). In addition, HLA-DM poly-
morphisms have been reported to confer an
increased relative risk for such varied entities as
rheumatoid arthritis (3), kidney transplant rejec-
tion (4), and membranous nephropathy (5). Since
HLA-DM is important in determining which
peptides are immunogenic, it may be as impor-
tant as MHC class II molecules in regulating the
immune response and therefore in conferring
susceptibility to infectious diseases.
Victor S. Sloan
University of Medicine and Dentistry of New Jersey
New Brunswick, New Jersey, USA
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Reply to V.S. Sloan: Dr. Sloan has rightly
pointed out the importance of HLA-DM in
regulating the immune response in rheumatoid
arthritis, kidney transplant rejection, and mem-
branous nephropathy. We did not mention the
role of HLA-DM because our review dealt solely
with infectious diseases that have well-
established HLA associations.
Neeloo Singh
Central Drug Research Institute
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ceftriaxone and convenience of outpatient paren-
teral therapy, this antibiotic was continued to
complete a 10-day course. On extensive questioning,
the patient denied contact with any cat, dog, or
other animal.  He had recently traveled to Nigeria
but denied even transient animal contact.
Since 1966, three cases of P. multocida epi-
glottitis have been reported (2-4). Although no
direct culture of the epiglottis was performed in
the present case, the clinical syndrome and the
absence of any other focus accounting for P.
multocida bacteremia strongly suggest that this
organism caused the epiglottitis. Including the
present case, three of the four reported cases
have occurred since 1993, which suggests that
either earlier cases were not recognized or the
incidence of this condition may be increasing. In
all three previous cases of P. multocida epiglot-
titis, the patients had cats as pets. As in the
current case, the clinical features of P. multo-
cida epiglottitis were indistinguishable from
epiglottitis secondary to more common bacterial
pathogens. However, the cases were all asso-
ciated with positive blood cultures. In contrast, a
23% rate of bacteremia was reported in a series of
epiglottitis cases in adults (including patients
with blood cultures positive for Haemophilus
influenzae type b or Group A streptococci)(5).
The vehicle of infection for this patient
remains unknown, as human-to-human trans-
mission has not been documented. This case
demonstrates that epiglottitis due to P. multo-
cida, a rare condition that may be increasing in
frequency, need not be accompanied by recognized
exposure to animals.
Michael Glickman and Robert S. Klein
Montefiore Medical Center and the Albert Einstein
College of Medicine, New York, New York, USA
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Hemolytic Uremic Syndrome
Surveillance to Monitor Trends in
Infection with Escherichia coli O157:H7
and Other Shiga Toxin-Producing
E. coli
To the Editor: In the past 15 years, knowledge
about the role of Shiga toxin-producing Esche-
richia coli (STEC) in human disease has expanded
rapidly. The most distinctive complication of
STEC infection is diarrhea-associated hemolytic
uremic syndrome (HUS), a major cause of acute
renal failure in U.S. children. Other manifes-
tations of STEC infection can range from mild
diarrhea to severe hemorrhagic colitis, thrombotic
thrombocytopenic purpura, and death (1). In the
United States, O157 is the most common STEC
and causes an estimated 20,000 infections and
250 deaths annually. E. Coli O157 outbreaks
associated with beef have caused concern among
public health workers, clinicians, and the public,
prompting major changes in clinical and labora-
tory practice, meat production, and food pre-
paration. However, critical questions remain
unanswered. Have prevention measures decreased
risk? Are new sources of STEC infections
emerging? Is the incidence of O157 infection
changing? How much illness is due to STEC of
serotypes other than O157?
Diarrhea-associated HUS is associated with
Shiga toxin, which is produced in quantity only
by STEC and by Shigella dysenteriae type 1;
approximately 90% of HUS cases are diarrhea-
associated (2,3). In the United States, where S.
dysenteriae type 1 infections are very rare, STEC
infections are the cause of virtually all diarrhea-
associated HUS. The incidence of HUS in North
America is about three cases per 100,000 chil-
dren under 5 years of age per year; the rate
among older children is somewhat lower, and the
rate among adults is not known (2-6). HUS
complicates approximately 5% to 10% of O157
infections and an unknown percentage of non-
O157 STEC infections (1). Except for supportive
care and hemodialysis, no treatment has been
shown to decrease the severity of illness or to pre-
vent complications. The sequelae of HUS—death
in 3% to 5% of cases (2,3,5) and long-term renal dys-
function in 10% to 30% of survivors (6)—and the
lack of specific therapy make prevention critical.